Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy

Chest

Volumn 145, Issue 4, 2014, Pages 729-737

  Tazawa, Ryushi ^a   Inoue, Yoshikazu ^b   Arai, Toru ^b   Takada, Toshinori ^c   Kasahara, Yasunori ^d   Hojo, Masayuki ^e   Ohkouchi, Shinya ^f   Tsuchihashi, Yoshiko ^g,h   Yokoba, Masanori ⁱ   Eda, Ryosuke ^j,k   Nakayama, Hideaki ^c,l   Ishii, Haruyuki ^m   Nei, Takahito ⁿ   Morimoto, Konosuke ^h   Nasuhara, Yasuyuki ^o   Ebina, Masahito ^f   Akira, Masanori ^b   Ichiwata, Toshio ^p   Tatsumi, Koichiro ^d   Yamaguchi, Etsuro ^q   Nakata, Koh ^a   more..

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^f TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Juzenkai Hopital   (Japan)

^h NAGASAKI UNIVERSITY   (Japan)

ⁱ KITASATO UNIVERSITY   (Japan)

^j NATIONAL SANYO HOSPITAL   (Japan)

^k Department of Medicine   (Japan)

^l TOKYO MEDICAL UNIVERSITY   (Japan)

^m KYORIN UNIVERSITY   (Japan)

ⁿ NIPPON MEDICAL SCHOOL   (Japan)

^o HOKKAIDO UNIVERSITY   (Japan)

^p TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^q AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGE; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENDER; HUMAN; LUNG ALVEOLUS PROTEINOSIS; MALE; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OXYGENATION; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; SEROLOGY; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; VITAL CAPACITY;

ADULT; AUTOIMMUNE DISEASES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY ALVEOLAR PROTEINOSIS; RESPIRATORY THERAPY; TIME FACTORS;

EID: 84898719735     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0603     Document Type: Article

References (27)

1. Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med. 1958; 258 (23): 1123-1142 .
2. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002; 166 (2): 215-235 .
3. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003; 349 (26): 2527-2539 .
4. Kitamura T, Tanaka N, Watanabe J, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colonystimulating factor. J Exp Med. 1999; 190 (6): 875-880 .
5. Uchida K, Nakata K, Trapnell BC, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood. 2004; 103(3): 1089-1098 .
6. Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994; 264 (5159): 713-716 .
7. Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A. 1994; 91(12): 5592-5596 .
8. Sakagami T, Beck D, Uchida K, et al. Patient-derived granulocyte/ macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med. 2010; 182 (1): 49-61 .
9. Seymour JF, Dunn AR, Vincent JM, Presneill JJ, Pain MC. Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis. N Engl J Med. 1996; 335(25): 1924-1925 .
10. Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic effi- cacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med. 2001; 163 (2): 524-531 .
11. Kavuru MS, Sullivan EJ, Piccin R, Thomassen MJ, Stoller JK. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2000; 161 (4 pt 1): 1143-1148 .
12. Venkateshiah SB, Yan TD, Bonfield TL, et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest. 2006 ; 130 (1): 227-237 .
13. Price A, Manson D, Cutz E, Dell S. Pulmonary alveolar proteinosis associated with anti-GM-CSF antibodies in a child: successful treatment with inhaled GM-CSF. Pediatr Pulmonol. 2006; 41 (4): 367-370 .
14. Schoch OD, Schanz U, Koller M, et al. BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF. Thorax. 2002 ; 57 (3): 277-280 .
15. Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res. 1999 ; 5 (9): 2316-2323 .
16. Tazawa R, Hamano E, Arai T, et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2005; 171(10): 1142-1149 .
17. Wylam ME, Ten R, Prakash UB, Nadrous HF, Clawson ML, Anderson PM. Aerosol granulocyte-macrophage colonystimulating factor for pulmonary alveolar proteinosis. Eur Respir J. 2006; 27 (3): 585-593 .
18. Tazawa R, Trapnell BC, Inoue Y, et al. Inhaled granulocyte/macrophage- colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2010 ; 181 (12): 1345-1354 .
19. Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008 ; 177 (7): 752-762 .
20. Ohashi K, Sato A, Takada T, et al. Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosis. Respir Med. 2012; 106 (2): 284-293 .
21. Uchida K, Beck DC, Yamamoto T, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med. 2007 ; 356 (6): 567-579 .
22. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143 (1): 29-36 .
23. Beccaria M, Luisetti M, Rodi G, et al. Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J. 2004 ; 23 (4): 526-531 .
24. Bonella F, Bauer PC, Griese M, Ohshimo S, Guzman J, Costabel U. Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients. Respir Med. 2011; 105 (12): 1908-1916 .
25. Seymour JF, Doyle IR, Nakata K, et al. Relationship of anti- GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax. 2003 ; 58 (3): 252-257 .
26. Campo I, Mariani F, Rodi G, et al. Assessment and management of pulmonary alveolar proteinosis in a reference center. Orphanet J Rare Dis. 2013 ; 8 : 40 .
27. Perez A IV, Coxson HO, Hogg JC, Gibson K, Thompson PF, Rogers RM. Use of CT morphometry to detect changes in lung weight and gas volume. Chest. 2005; 128 (4): 2471-2477 .